Earnings Conference Call: Veracyte, Inc. held its Q2 2025 earnings conference call on August 6, 2025, featuring key executives including CEO Marc Stapley and CFO Rebecca Chambers, discussing the company's financial results and future outlook.
Participant Engagement: The call included participation from various research analysts representing major financial institutions, indicating strong interest in Veracyte's performance and strategic direction.
VCYT
$43.015+Infinity%1D
Analyst Views on VCYT
Wall Street analysts forecast VCYT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 42.17 USD with a low forecast of 28.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast VCYT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 42.17 USD with a low forecast of 28.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 42.840
Low
28.00
Averages
42.17
High
48.00
Current: 42.840
Low
28.00
Averages
42.17
High
48.00
Morgan Stanley
Tejas Savant
Underweight
maintain
$28 -> $40
2025-11-11
Reason
Morgan Stanley
Tejas Savant
Price Target
$28 -> $40
2025-11-11
maintain
Underweight
Reason
Morgan Stanley analyst Tejas Savant raised the firm's price target on Veracyte to $40 from $28 and keeps an Underweight rating on the shares.
Guggenheim
maintain
2025-11-07
Reason
Guggenheim
Price Target
2025-11-07
maintain
Reason
Guggenheim notes that NCCN guidelines for prostate cancer V3.2026 were released and include updates to the principles of risk stratification and biomarkers sections. The principles of risk stratification tables include only Decipher from Veracyte and the MMAI test from Artera AI for intermediate risk prostate cancer and high-risk/very-high-risk prostate cancer, and only Decipher for BCR post-RP. At first look, the firm says this is an incrementally positive update for Veracyte's Decipher as the test continues to be differentiated from other genomic classifier tests based on robust clinical evidence and inclusion in the principles of risk stratification table. Guggenheim has a Buy rating on Veracyte.
UBS
Lu Li
Buy
maintain
$42 -> $48
2025-11-05
Reason
UBS
Lu Li
Price Target
$42 -> $48
2025-11-05
maintain
Buy
Reason
UBS analyst Lu Li raised the firm's price target on Veracyte to $48 from $42 and keeps a Buy rating on the shares.
Canaccord
Kyle Mikson
Hold
maintain
$40 -> $43
2025-11-05
Reason
Canaccord
Kyle Mikson
Price Target
$40 -> $43
2025-11-05
maintain
Hold
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Veracyte to $43 from $40 and keeps a Hold rating on the shares. The firm said the company demonstrated strong execution in 3Q25, although they remain on the sidelines until they gain visibility to and confidence in long-term growth drivers.
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
